ID

38234

Beschreibung

Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib; ODM derived from: https://clinicaltrials.gov/show/NCT02056080

Link

https://clinicaltrials.gov/show/NCT02056080

Stichworte

Versionen (1)
  1. 30.09.19 30.09.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

30. September 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Neoplasm NCT02056080

Englisch

Eligibility Breast Neoplasm NCT02056080

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
confirmed diagnosis of metastatic breast cancer her2-positive phenotype (confirmed by ihc 3 + or fish positive)
Beschreibung

Secondary malignant neoplasm of female breast HER2 Positive Immunohistochemistry | Secondary malignant neoplasm of female breast HER2 Positive FISH Positive

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0346993
UMLS CUI [1,2]
C2348909
UMLS CUI [1,3]
C0021044
UMLS CUI [2,1]
C0346993
UMLS CUI [2,2]
C2348909
UMLS CUI [2,3]
C0162789
UMLS CUI [2,4]
C1514241
older than 18 years
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
progressed to at least one prior treatment line for mbc with trastuzumab and / or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes
Beschreibung

Prior Therapy Quantity Secondary malignant neoplasm of female breast | trastuzumab | lapatinib | Combined Modality Therapy | Chemotherapy | Hormone Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0346993
UMLS CUI [2]
C0728747
UMLS CUI [3]
C1506770
UMLS CUI [4]
C0009429
UMLS CUI [5]
C0392920
UMLS CUI [6]
C0279025
having the patient's complete medical history that contains all lines antiher2 therapy treatment
Beschreibung

Medical History | Targeted Therapy HER2 Quantity

Datentyp

boolean

Alias
UMLS CUI [1]
C0262926
UMLS CUI [2,1]
C2985566
UMLS CUI [2,2]
C0069515
UMLS CUI [2,3]
C1265611
being a patient who initiated the combination of trastuzumab and lapatinib between january 2005 and december 2011
Beschreibung

Initiation Lapatinib/Trastuzumab Regimen

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1704686
UMLS CUI [1,2]
C1541246
inform the patient and get the signature of the informed consent
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
not having phenotypic classification of the tumor by ihc or fish test for her2
Beschreibung

Absence Immunohistochemistry Neoplasm HER2 | Absence FISH Neoplasm HER2

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0021044
UMLS CUI [1,3]
C0027651
UMLS CUI [1,4]
C0069515
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0162789
UMLS CUI [2,3]
C0027651
UMLS CUI [2,4]
C0069515
being a patient with her2-negative phenotype(fish negative or ihc in range [0-2 +] without fish)
Beschreibung

Patient HER2 Negative FISH Negative | Patient HER2 Negative Immunohistochemistry

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C2348908
UMLS CUI [1,3]
C0162789
UMLS CUI [1,4]
C1513916
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C2348908
UMLS CUI [2,3]
C0021044
being a patient who received the trastuzumab and/or lapatinib treatment (tl) in combination with chemotherapy
Beschreibung

Lapatinib/Trastuzumab Regimen | Chemotherapy | Combined Modality Therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C1541246
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0009429
being a patient who, since january 2012, began tl therapy for metastatic disease.
Beschreibung

Lapatinib/Trastuzumab Regimen Neoplasm Metastasis | Start time

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1541246
UMLS CUI [1,2]
C0027627
UMLS CUI [2]
C1301880
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Breast Neoplasm NCT02056080

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Secondary malignant neoplasm of female breast HER2 Positive Immunohistochemistry | Secondary malignant neoplasm of female breast HER2 Positive FISH Positive
Item
confirmed diagnosis of metastatic breast cancer her2-positive phenotype (confirmed by ihc 3 + or fish positive)
boolean
C0346993 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C0346993 (UMLS CUI [2,1])
C2348909 (UMLS CUI [2,2])
C0162789 (UMLS CUI [2,3])
C1514241 (UMLS CUI [2,4])
Age
Item
older than 18 years
boolean
C0001779 (UMLS CUI [1])
Prior Therapy Quantity Secondary malignant neoplasm of female breast | trastuzumab | lapatinib | Combined Modality Therapy | Chemotherapy | Hormone Therapy
Item
progressed to at least one prior treatment line for mbc with trastuzumab and / or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])
C0009429 (UMLS CUI [4])
C0392920 (UMLS CUI [5])
C0279025 (UMLS CUI [6])
Medical History | Targeted Therapy HER2 Quantity
Item
having the patient's complete medical history that contains all lines antiher2 therapy treatment
boolean
C0262926 (UMLS CUI [1])
C2985566 (UMLS CUI [2,1])
C0069515 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Initiation Lapatinib/Trastuzumab Regimen
Item
being a patient who initiated the combination of trastuzumab and lapatinib between january 2005 and december 2011
boolean
C1704686 (UMLS CUI [1,1])
C1541246 (UMLS CUI [1,2])
Informed Consent
Item
inform the patient and get the signature of the informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Absence Immunohistochemistry Neoplasm HER2 | Absence FISH Neoplasm HER2
Item
not having phenotypic classification of the tumor by ihc or fish test for her2
boolean
C0332197 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C0027651 (UMLS CUI [1,3])
C0069515 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C0162789 (UMLS CUI [2,2])
C0027651 (UMLS CUI [2,3])
C0069515 (UMLS CUI [2,4])
Patient HER2 Negative FISH Negative | Patient HER2 Negative Immunohistochemistry
Item
being a patient with her2-negative phenotype(fish negative or ihc in range [0-2 +] without fish)
boolean
C0030705 (UMLS CUI [1,1])
C2348908 (UMLS CUI [1,2])
C0162789 (UMLS CUI [1,3])
C1513916 (UMLS CUI [1,4])
C0030705 (UMLS CUI [2,1])
C2348908 (UMLS CUI [2,2])
C0021044 (UMLS CUI [2,3])
Lapatinib/Trastuzumab Regimen | Chemotherapy | Combined Modality Therapy
Item
being a patient who received the trastuzumab and/or lapatinib treatment (tl) in combination with chemotherapy
boolean
C1541246 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Lapatinib/Trastuzumab Regimen Neoplasm Metastasis | Start time
Item
being a patient who, since january 2012, began tl therapy for metastatic disease.
boolean
C1541246 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C1301880 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video